Quality,Economics, and National Guidelines for Transcatheter Aortic Valve Replacement |
| |
Authors: | Peter M. Pollak Michael J. Mack David R. Holmes Jr. |
| |
Affiliation: | 1. Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, MN;2. The Heart Hospital Baylor, Plano, TX |
| |
Abstract: | ![]() Transcatheter aortic valve replacement (TAVR) is a transformative technology for the treatment of aortic stenosis, requiring a multidisciplinary collaboration in the form of a “heart team” that includes interventional cardiologists and cardiac surgeons. As this new technology continues to disperse rapidly, its proper therapeutic role evolves and leads to important questions regarding who should perform the procedure, where it should be performed, and who should pay for it. Herein, we review the most recent guidelines governing the use of TAVR in the United States and Europe. We then summarize the available registry data, which, despite its limitations, presents the clearest picture of TAVR in clinical use. Finally, we discuss the costs and relative cost-effectiveness of TAVR. Taken together, these are the elements from which the larger questions surrounding TAVR must be answered. |
| |
Keywords: | ACC, American College of Cardiology AS, aortic stenosis AUC, appropriate use criteria AVR, aortic valve replacement CMS, Center for Medicare Services CV, cardiovascular DRG, diagnostic-related group ICER, incremental cost-effectiveness ratio LOS, length of stay LY, life-years NCD, National Coverage Determination PARTNER, Placement of Aortic Transcatheter Valve PROM, predictive risk of mortality QALY, quality-adjusted life-year SAVR, surgical aortic valve replacement STS, Society of Thoracic Surgery TA, transapical TAVR, transcatheter aortic valve replacement TF, transfemoral THV, transcatheter heart valve SAVR, surgical aortic valve replacement TVTR, Transcatheter Valve Therapy Registry US, United States VHD, valvular heart disease |
本文献已被 ScienceDirect 等数据库收录! |
|